• Curis consented the first six patients in its TakeAim CLL Phase 2 study of emavusertib with zanubrutinib.
• Guidance reaffirmed for dosing five CLL patients by end-July 2026; initial data expected in December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE98101) on July 06, 2026, and is solely responsible for the information contained therein.